Skip to main content
Premium Trial:

Request an Annual Quote

Mercy BioAnalytics: Myla Lai-Goldman

Myla Lai-Goldman has been appointed to the board of directors of Mercy BioAnalytics, a company developing extracellular vesicle-based liquid biopsy tests for early cancer detection. Most recently, she was executive VP as well as chief medical and chief scientific officer at Laboratory Corporation of America, where she worked for more than 18 years. She is also a cofounder and chairperson of GeneCentric Therapeutics, where she was previously president and CEO. In addition, she is a venture partner at Hatteras Venture Partners and a managing partner at Personalized Science, a diagnostic consulting company. Lai-Goldman holds an MD from Columbia University College of Physicians and Surgeons.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.